Precision Diagnostics and Medicine Market – Trends Forecast Till 2031

Market Snapshot

Market Overview

The global Precision Diagnostics and Medicine Market size was estimated at USD 143,530 million in 2024 and is projected to reach USD 323,095.0 million in 2031 at a CAGR of 12.29 % during the forecast period 2025-2031.

Precision diagnostics and medicine is a rapidly evolving field that focuses on tailoring healthcare treatments and diagnostic procedures to the individual characteristics of each patient. It involves using advanced technologies such as genomics, proteomics, and biomarkers to provide more accurate, personalized healthcare solutions. This approach aims to enhance the effectiveness of treatments by considering genetic, environmental, and lifestyle factors that influence a patient's health. It contrasts with traditional medicine, which often uses a one-size-fits-all model of treatment based on general population data.

The scope of precision diagnostics and medicine extends across a wide range of healthcare areas, including oncology, cardiology, neurology, and infectious diseases. In oncology, for example, precision medicine enables clinicians to target specific genetic mutations in cancer cells, leading to more effective treatments with fewer side effects. Similarly, in cardiology, tailored therapies based on genetic profiles help manage conditions such as arrhythmias and heart disease. The scope also covers the development of advanced diagnostic tools that can predict diseases before symptoms appear, enabling earlier intervention and better management of chronic conditions.

Several key trends are shaping the precision diagnostics and medicine market. The integration of artificial intelligence and machine learning with diagnostic tools is enhancing the ability to analyze complex data sets, such as genomic sequences, to identify patterns and predict health outcomes. Another significant trend is the growing adoption of liquid biopsy techniques, which offer non-invasive methods for detecting genetic mutations and monitoring disease progression. Furthermore, the increasing demand for personalized treatments driven by patient preferences for more tailored healthcare options is fueling market growth. As these technologies evolve, they are expected to improve healthcare outcomes and reduce overall treatment costs.

The drivers of the precision diagnostics and medicine market include advancements in genomic research, decreasing costs of sequencing technologies, and increased investments in healthcare innovation. With more comprehensive and accessible genetic data, the potential for precision medicine to revolutionize healthcare is greater than ever. Additionally, the shift toward value-based care, which focuses on improving patient outcomes and reducing costs, has encouraged the adoption of precision diagnostics. Regulatory support, such as the approval of precision therapies by health authorities, and growing patient awareness of personalized medicine also play a crucial role in accelerating market growth.

Delvens Industry Expert's Standpoint

Experts in the Precision Diagnostics and Medicine Market highlight several key trends driving growth and innovation. Precision diagnostics and medicine is a rapidly growing field that tailors healthcare treatments and diagnostics to individual patient characteristics using advanced technologies like genomics and biomarkers. It spans areas such as oncology, cardiology, and neurology, offering personalized treatment options based on genetic, environmental, and lifestyle factors. Key trends driving the market include the integration of AI and machine learning, non-invasive diagnostic techniques like liquid biopsies, and increasing demand for personalized treatments. The market is further fueled by advancements in genomic research, decreasing sequencing costs, and regulatory support, all of which contribute to improved healthcare outcomes and cost-efficiency.

Market Portfolio

Key Findings

• The genetic testing segment dominated the precision diagnostics market, by type, in recent years. The precision diagnostics market is categorized into genetic testing, DTC testing, and other tests. The genetic testing segment held the largest share in the market, as these tests are used to detect genetic variations in genes to diagnose, predict, or manage diseases. The segment's substantial share is driven by increasing research and investments aimed at developing advanced genetic tests for various diseases.

• The oncology segment led the precision medicine market, by indication, in recent years. The precision medicine market is segmented by indications, including oncology, rare diseases, infectious diseases, hematological disorders, and other indications. The oncology segment captured the largest share of the market, with pharmaceutical companies focusing heavily on developing precision therapies for cancers like breast cancer, lung cancer, and prostate cancer, among others. These companies are exploring various drug modalities to create precision cancer treatments. For example, in recent years, the US FDA approved several precision cancer therapies, including inhibitors and monoclonal antibodies. This segment's strong growth is also fueled by rising collaborations and investments between pharmaceutical companies, such as a recent partnership between Boehringer Ingelheim and Circle Pharma to develop cyclin inhibitors for inhibiting cancer cell growth.

• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America region is projected to hold the largest market share. Factors such as advancements in genomic medicine, increased awareness of personalized healthcare, AI integration, rising demand for early disease detection, technological innovations, chronic disease prevalence, government support, regulatory approvals, healthcare collaborations, and improved infrastructure have triggered the Precision Diagnostics and Medicine Market in the region.

Regional Analysis

North America to Dominate the Market

• North America: North America, particularly the U.S., dominated the precision diagnostics market, driven by its advanced healthcare infrastructure and strong biotechnology research sectors. Continuous investments in these areas have resulted in innovations that enhance the efficiency and reliability of personalized diagnostics technologies. Government initiatives to improve healthcare quality and accessibility, coupled with substantial funding for research and development, have further fuelled market growth.

• Europe: Europe’s precision diagnostics market has seen significant growth, fueled by technological advancements, rising healthcare expenditures, and an increasing focus on personalized medicine. The region’s regulatory environment is adapting to support new diagnostic technologies, and collaborations between companies, research institutions, and healthcare providers are driving innovation. In countries like the UK, France, and Germany, government support for precision medicine initiatives has accelerated the adoption of precision diagnostics, creating a favorable market environment.

• Asia Pacific: The precision diagnostics market in the Asia Pacific region is expanding rapidly, particularly in countries like China and India, where improvements in healthcare infrastructure and government support for advanced healthcare technologies are enhancing market potential. The rising prevalence of chronic diseases such as cancer and diabetes, along with increased awareness of personalized treatments, has further driven market growth. Research and development investments, along with collaborations between public and private sectors, are also key contributors to the rapid expansion.

• Middle East & Africa: The Middle East & Africa region is witnessing rapid growth in the precision diagnostics market, with significant investments in healthcare infrastructure and advanced medical facilities. Rising chronic diseases such as diabetes, cardiovascular diseases, and cancer are driving the demand for early and accurate diagnostic solutions. Countries like Saudi Arabia and Kuwait are making notable strides with government initiatives to enhance healthcare technologies, including funding for research and the adoption of digital health innovations like AI, which boosts the accuracy and efficiency of precision diagnostics.

Competitive Landscape

• F. HOFFMANN-LA ROCHE LTD (DIAGNOSTICS)
• ABBOTT
• AGILENT TECHNOLOGIES, INC.
• GUARDANT HEALTH
• EXACT SCIENCES CORPORATION
• QIAGEN
• MYRIAD GENETICS, INC.
• NATERA, INC.
• ILLUMINA, INC.
• THERMO FISHER SCIENTIFIC INC.
• DANAHER
• 23ANDME, INC.
• MERCK & CO., INC.
• GILEAD SCIENCES, INC.
• F. HOFFMANN-LA ROCHE LTD (MEDICINE)
• BRISTOL-MYERS SQUIBB COMPANY
• NOVARTIS AG
• ASTRAZENECA
• ABBVIE INC.
• LILLY
• PFIZER INC.
• SAREPTA THERAPEUTICS, INC.
• VERTEX PHARMACEUTICALS INCORPORATED
• GSK PLC.
• SANOFI
• JOHNSON & JOHNSON SERVICES, INC.
• AMGEN INC.
• MERCK KGAA
• ALNYLAM PHARMACEUTICALS, INC.
• INCYTE
• ARUP LABORATORIES
• DEVYSER
• DIASORIN S.P.A.
• TEMPUS
• PILLAR BIOSCIENCES INC.
• INVIVOSCRIBE, INC.
• NEUROCODE
• C2N DIAGNOSTICS
• TRINITY BIOTECH
• AMOY DIAGNOSTICS CO., LTD.

Recent Developments

• In November 2024, Roche was granted the CE Mark for its VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, designed to identify epithelial ovarian cancer (EOC) patients who are eligible for treatment with ELAHERE (mirvetuximab soravtansine) for FRα-positive platinum-resistant ovarian cancer.

• In September 2024, Foundation Medicine partnered with Syndax Pharmaceuticals to develop a companion diagnostic aimed at identifying acute myeloid leukemia (AML) patients carrying the NPM1 mutation.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
• Gain authentic and granular data access for the Precision Diagnostics and Medicine Market to understand the trends and the factors involved in changing market situations.
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope